SCHEMBL6712737

SCHEMBL6712737

O=c1occ2[nH]c3ccccc3cc1-2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.57
CHEK1 O14757 1/20 0.57
RAB9A P51151 5/20 0.46
NPC1 O15118 4/20 0.46
KDM4E B2RXH2 5/20 0.45
MAPT P10636 5/20 0.45
HPGD P15428 4/20 0.45
MEN1 O00255 3/20 0.45
ALDH1A1 P00352 3/20 0.45
KMT2A Q03164 3/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
DAO P14920 2/20 0.43
BRD4 O60885 1/20 0.43
DDO Q99489 1/20 0.43
PDGFRB P09619 1/20 0.43
FGFR1 P11362 1/20 0.43
CASP3 P42574 2/20 0.41
SENP8 Q96LD8 2/20 0.41
SENP7 Q9BQF6 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31059216 0.76 KDR (0.53) KDRCHEK1RAB9ANPC1KDM4E
SCHEMBL2430291 0.76 CHEK1 (0.61) KDRCHEK1RAB9ANPC1KDM4E
SCHEMBL29370693 0.73 KDR (1.00) KDRCHEK1RAB9ANPC1KDM4E
SCHEMBL5076094 0.73 KDR (1.00) KDRCHEK1RAB9ANPC1KDM4E
SCHEMBL19290 0.71 KDR (0.61) KDRCHEK1RAB9ANPC1KDM4E
SCHEMBL1618522 0.70 KDR (0.64) KDRCHEK1RAB9ANPC1KDM4E
SCHEMBL374022 0.70 RAB9A (0.74) KDRCHEK1RAB9ANPC1KDM4E
SCHEMBL29631691 0.70 RAB9A (0.74) KDRCHEK1RAB9ANPC1KDM4E
SCHEMBL8086286 0.69 KDR (0.58) KDRCHEK1RAB9ANPC1KDM4E
SCHEMBL8788050 0.69 IL4I1 (0.53) KDRCHEK1RAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040198981-A1 Tricyclic dihydroquinoline derivatives,method for preparing same and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2004-10-07 US disclosed
US-20040180917-A1 Novel tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing the same HUSSON HENRI-PHILIPPE (FR) 2004-09-16 US disclosed
EP-1103554-B9 Derivatives of dihydrofuro-(3,4-b)-quinolein-1-ones, process of préparation and phamaceutical compositions containing them SERVIER LAB (FR) 2003-12-17 EP disclosed
US-6548515-B1 Use as anticancer agents LES LABORATORIES SERVIER (FR) 2003-04-15 US disclosed
EP-1103554-B1 Derivatives of dihydrofuro-(3,4-b)-quinolein-1-ones, process of préparation and phamaceutical compositions containing them SERVIER LAB (FR) 2003-03-12 EP disclosed
EP-1103554-A1 Derivatives of dihydrofuro-(3,4-b)-quinolein-1-ones, process of préparation and phamaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2001-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180917-A1 Novel tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing the same SCN11A, CYP4A11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 KDR 3944/4885CHEK1 2542/4885RAB9A 182/4885
US-20040198981-A1 Tricyclic dihydroquinoline derivatives,method for preparing same and pharmaceutical compositions containing same CYP2C8, CYP2D6, UGT1A8 KDR 2777/4885CHEK1 3176/4885RAB9A 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.